# Extracellular ATP and UTP exert similar effects on rat isolated hepatocytes

<sup>1</sup>Stefaan Keppens, Ann Vandekerckhove & Henri De Wulf

Afdeling Biochemie, Campus Gasthuisberg, Faculteit Geneeskunde, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium

1 Extracellular UTP and ATP show obvious similarities in their control of several metabolic functions of rat isolated hepatocytes.

2 They have a similar time-course and concentration-dependency for the activation of glycogen phosphorylase, the generation of inositol trisphosphate (IP<sub>3</sub>), the inhibition of glycogen synthase and the lowering of adenosine 3': 5'-cyclic monophosphate (cyclic AMP) levels.

- 3 There is a similar synergism of the nucleotides with glucagon in activating phosphorylase.
- 4 They undergo a similar inhibition by phorbol myristic acid of their glycogenolytic effect.
- 5 The ATP and UTP effect on  $IP_3$  levels are not additive.
- 6 It is tentatively concluded that UTP and ATP use a common receptor.

Keywords: ATP; UTP; rat hepatocytes; glycogen metabolism

### Introduction

Extracellular adenine nucleotides regulate many important cell functions in several different tissues through an interaction with P<sub>2</sub>-purinoceptors, which can be subdivided into P<sub>2x</sub> and P<sub>2y</sub> receptors according to the rank order of potency of several ATP analogues (Burnstock & Kennedy, 1985). P<sub>2y</sub>-purinoceptors are characterized by the rank order of potency: 2-methylthio-ATP  $\gg$  ATP = ADP  $> \alpha_{,\beta}$ -methylene-ATP. P<sub>2x</sub>-receptors are more specific for  $\alpha_{,\beta}$ -methylene-ATP than for ATP and 2-methylthio-ATP. Moreover the P<sub>2x</sub> effect of ATP can be desensitized by pretreatment with  $\alpha_{,\beta}$ -methylene-ATP (see Gordon, 1986, for a review).

UTP and other uracyl nucleotides also regulate various functions in many different cell types, as reviewed by Seifert & Schultz (1989). These authors presented evidence that in several tissues and cell types the pyrimidine nucleotides exert their effects by interacting with a specific pyrimidinoceptor rather than by interacting with the purinoceptor. This view has recently been refined by O'Conner et al. (1991). Taking into account all nucleotide effects these authors propose that the nucleotide receptors can be subdivided into three classes:  $P_{2Y}$ -purinoceptors with 2-methylthio-ATP  $\ge$  ATP = ADP > UTP, 'Nucleotide' receptors with UTP = ATP > ADP > 2methylthio-ATP and a 'mixed' type of receptor with 2methylthio-ATP > ATP = UTP = ADP as their respective rank order of potencies. The relative densities and coupling affinities of these receptors can, according to the authors, vary considerably from tissue to tissue.

Rat liver parenchymal cells possess purinoceptors activated by extracellular ATP. Binding of the nucleotide to these receptors leads to the activation of phospholipase C, generating diacylglycerol and inositol-(1,4,5)-trisphosphate (IP<sub>3</sub>). IP<sub>3</sub> induces a rise in cytosolic calcium (Berridge & Irvine, 1989) leading to the activation of glycogen phosphorylase, which is responsible for glycogen breakdown. Diacylglycerol stimulates the activity of protein kinase C which results, among other effects, in the inactivation of glycogen synthase, in combination with the inhibition by calcium of glycogen synthase phosphatase (Mvumbi *et al.*, 1985).

Based on the rank order of the glycogenolytic potency of different ATP analogues, we (Keppens & De Wulf, 1986) and others (Gordon, 1986) have proposed that the purinoceptor involved in glycogenolysis belongs to the  $P_{2Y}$ -subclass in the nomenclature of Burnstock & Kennedy (1985). However, our results recently obtained with 2-methylthio-ATP (Keppens &

De Wulf, 1991) suggest some heterogeneity for the  $P_{2Y}$ -purinoceptor. Indeed although 2-methylthio-ATP has been shown to be a more potent glycogenolytic agonist than ATP, some other effects were not compatible with the existence of a common receptor for both nucleotides: (a) 2-methylthio-ATP shows little affinity for the  $P_{2Y}$ -receptor characterized with ATPa[<sup>35</sup>S]; (b) 2-methylthio-ATP has little effect on the levels of IP<sub>3</sub>, and (c) it has no effect on the levels of cyclic AMP increased previously by glucagon (Keppens & De Wulf, 1991).

So far, the only information about effects of UTP on liver comes from the work of Häussinger *et al.* (1987, 1988). These authors used the perfused rat liver to study the effects of both ATP and UTP and reported a different time-course for the glucose release from the liver on perfusion with either ATP or UTP. Differences in portal vein pressure, K<sup>+</sup> uptake, calcium and thromboxane release and in oxygen consumption were also observed in their studies. Although they suggested that the effects of ATP were mediated by  $P_{2Y}$ -purinoceptors and those of UTP by a different receptor (Häussinger *et al.*, 1987) they were conscious of the fact that there is a complex interaction between hepatic parenchymal and non-parenchymal cells (Häussinger *et al.*, 1988).

The present study compares several effects of ATP and UTP at the level of the liver parenchymal cell, avoiding contribution by other substances, possibly released by ATP or UTP from non-parenchymal cells. The aims of this study were to substantiate the glycogenolytic effect of extracellular UTP on hepatocytes and to compare these effects of UTP with those induced by ATP.

## Methods

Adult male Wistar-strain albino rats (200-250 g body wt.) fed ad libitum with a standard laboratory chow were used.

Isolation and incubation of the hepatocytes were done as previously described (Vandenheede *et al.*, 1976). Briefly, the liver was removed from the animal, cleared of blood and then perfused at 37°C for about 10min with a Krebs-Henseleit bicarbonate buffer without calcium. Subsequently, collagenase (30 mg 100 ml<sup>-1</sup> of perfusion buffer) and calcium (2.5 mM) were added and the perfusion was continued for another 25–30 min. The hepatocytes were harvested and incubated at 37°C (or at 10°C when indicated) in a Krebs-Henseleit buffer containing 10 mM glucose in closed plastic vials saturated with 95% O<sub>2</sub>, 5% CO<sub>2</sub> (v/v). Cyclic AMP and IP<sub>3</sub> concentrations were

<sup>&</sup>lt;sup>1</sup> Author for correspondence.

determined with a competitive protein-binding technique, the former based on the procedure described by Gilman (1970), using an assay kit from the Radiochemical Centre (Amersham, Bucks., U.K.) and the latter based on the method described by Bredt *et al.* (1989) with slight modifications. Cerebellar membranes, known to contain high amounts of specific IP<sub>3</sub> binding protein (Worley *et al.*, 1987) were prepared by homogenization and repetitive centrifugation of rabbit cerebellum. The incubation medium contained about 50  $\mu$ g of these membranes, 1 nM [<sup>3</sup>H]-IP<sub>3</sub> and 10 $\mu$ l cell extract in a final volume of 100 $\mu$ l. Bound and free ligand were separated after 10 min of incubation by filtration through Whatman GF/A filters, which were washed three times with 7 ml 50 mM Tris-HCl (pH 8.4) and 1 mM EDTA. Radioactivity was then determined by liquid scintillation counting.

UTP and ATP were from Sigma Chemical Co., St. Louis, MO, U.S.A.; [<sup>3</sup>H]-inositol-(1,4,5)-trisphosphate was from Amersham International, Amersham, Bucks., U.K.; glucagon was from Novo Laboratories, Copenhagen, Denmark. Suramin was a gift from Bayer Belgium, Pharma division, Brussels, Belgium.

The curve fitting programme 'Enzfitter' (Leatherbarrow, 1987) was from Elsevier Biosoft (Cambridge, U.K.) and was used to fit the experimental data to a Michaelean-type of equation (concentration-dependent effects).

### Results

To compare the effects of ATP and UTP we measured their capacity to activate glycogen phosphorylase, to increase  $IP_3$  levels, to inhibit the rise in cyclic AMP levels after glucagon and to inactivate glycogen synthase.

First we determined the kinetics of these effects of ATP and UTP (Figure 1). The activation of glycogen phosphorylase by  $5\mu M$  UTP and ATP was rapid, reached maximal levels of phosphorylase a within 20s and declined afterwards. The effect of  $10\mu M$  ATP and UTP on the levels of IP<sub>3</sub> was even more rapid and transient than the activation of phosphorylase, reaching maximal levels after 5s. Finally, the inactivation of glycogen synthase by  $5\mu M$  ATP and UTP and UTP and the cyclic AMP-lowering effect of 1 mm ATP and UTP were maximal within 1 min and again no differences between ATP and UTP were seen.

Next we determined the concentration-dependencies of these four parameters. Figure 2 illustrates the effects of increasing concentrations of ATP and of UTP on the activation of phosphorylase (at 20s), on the increase of IP<sub>3</sub> levels (at 5s), on the decrease of cyclic AMP levels (at 1 min) and on the inactivation of synthase (at 1 min). The curves on the figure and the concentrations at which half-maximal effects were obtained (K-values, see below) were computer-generated by applying a Michaelean-type of equation to the data. The data show a complete similarity between ATP and UTP effects on the liver parenchymal cell. Indeed, both nucleotides were equipotent in activating phosphorylase ( $K_a = 1.1 \, \mu$ M), increasing the levels of IP<sub>3</sub> ( $K_{IP} = 40 \, \mu$ M), lowering the cyclic AMP levels ( $K_c = 15 \, \mu$ M) and inactivating synthase ( $K_s = 5 \, \mu$ M).

In order to compare further ATP and UTP effects on the liver parenchymal cell, we checked whether UTP, like ATP, could act synergistically with glucagon. For ATP it has already been shown that glucagon increases the ability of ATP to augment the levels of cytosolic calcium (Charest *et al.*, 1985). Figure 3 illustrates that a synergism can also be demonstrated by measuring the activation of phosphorylase at low temperatures (10°C) where there is only a very moderate effect of glucagon and of ATP or UTP separately. The combination of either ATP or UTP with glucagon resulted in a pronounced and similar activation of phosphorylase, presumably due to an increase in the cytosolic calcium levels.

We next used the  $P_2$ -purinoceptor antagonist, suramin (Dunn & Blakely, 1988) and procion blue, a  $P_{2Y}$ -antagonist (Burnstock & Warland, 1987). Figure 4 shows that the glyco-



Figure 1 Comparison of the time-dependent activation of glycogen phosphorylase, increase of inositol trisphosphate (IP<sub>3</sub>) levels, inactivation of glycogen synthase and inhibition of the rise in cyclic AMP levels. Hepatocytes were pre-incubated for 20-30 min in the presence of 10mM glucose and were then challenged with ATP ( $\bigcirc$ ) or UTP ( $\bigcirc$ ) (both at 5  $\mu$ M) for the effects on phosphorylase and synthase, at 10  $\mu$ M for the increase in IP<sub>3</sub> levels and at 1 mM for lowering cyclic AMP levels. Samples were taken at the indicated times. (a) Phosphorylase activation; (b) IP<sub>3</sub> increase; (c) inactivation of synthase and (d) lowering of cyclic AMP levels in hepatocytes previously treated for 1 min with 20 nM glucagon. Data shown are representative of 3-5 independent experiments.

genolytic effect of ATP, UTP or vasopressin was not inhibited by low concentrations ( $20 \mu M$ ) of either P<sub>2</sub>-antagonist. Figure 4 further illustrates that the inhibitory effect of higher concentrations of the antagonists ( $400 \mu M$ ) is non-specific since the glycogenolytic effect of vasopressin (Figure 4c) was equally well counteracted. Even the glycogenolytic effect of glucagon was inhibited by these high concentrations of suramin and procion-blue (not shown).

To check further the possibility that UTP (or ATP) might interact with a  $P_{2x}$  type of receptor, we used  $\alpha_{\beta}$ -methylene-ATP, which, in other tissues, is able to induce a desensitization of the  $P_{2x}$ -mediated effect (Burnstock & Kennedy, 1985). Pretreatment of the hepatocytes for 5 min with 200  $\mu$ M



Figure 2 Comparison of the concentration-dependencies of ATP and UTP for the activation of glycogen phosphorylase, the increase in inositol trisphosphate (IP<sub>3</sub>) levels, the inactivation of glycogen synthase and the inhibition of the rise in cyclic AMP levels. Hepatocytes were pre-incubated with 10 mM glucose for 20-30 min and then challenged with increasing concentrations of either ATP ( $\bigcirc$ ) or UTP ( $\bigcirc$ ). (a) Phosphorylase *a* levels after 20s; (b) IP<sub>3</sub> levels after 5s; (c) synthase *a* levels after 1 min and (d) cyclic AMP levels after 1 min (glucagon (20 nM) was added 1 min prior to the addition of the nucleotides). Data, expressed as percentage changes from control values, are mean values of at least 5 independent experiments; s.e.mean did not exceed 10%.

of  $\alpha,\beta$ -methylene-ATP did not desensitize the glycogenolytic effect of UTP (or of ATP).

The effect of both agonists on phosphorylase activation was equally counteracted by phorbol myristic acid. Indeed, pretreatment of the hepatocytes for 5 min with  $1.6 \,\mu$ M of the phorbol ester increased the  $K_a$  value 2 to 3 fold.

Finally we tested whether the ATP and UTP effects were additive. Since the activation of glycogen phosphorylase, the lowering of cyclic AMP levels after glucagon and the inactivation of synthase were all maximal, we looked for a possible additivity of ATP and UTP effects on the levels of IP<sub>3</sub>. Figure 5 shows the IP<sub>3</sub> levels obtained after addition of supramaximal concentrations of ATP, UTP or of vasopressin either



Figure 3 Synergistic effect between ATP or UTP and glucagon on the activation of glycogen phosphorylase. Hepatocytes were preincubated for 20min at 37°C with 10mM glucose. They were then brought to 10°C and kept at this temperature for at least 15min before adding increasing concentrations of glucagon either alone ( $\blacktriangle$ ) or with 5 $\mu$ M ATP ( $\bigcirc$ ) or UTP ( $\bigcirc$ ). Samples were taken 10min later for the determination of the levels of phosphorylase *a*.

alone or in combination with each other. It is clear that the effect of ATP and UTP on the levels of  $IP_3$  were not additive, in contrast to the additive effects of these nucleotides with vasopressin.

## Discussion

It is clear from these data that ATP and UTP exert very similar effects on isolated hepatocytes. Indeed, both the timeand concentration-dependent activation of phosphorylase by UTP and ATP are completely identical (Figure 1, see also Keppens & De Wulf, 1985, and Charest et al., 1985). Since the activation of phosphorylase by ATP has been shown to be linked to increased levels of  $IP_3$  (Charest *et al.*, 1985) a similar situation might exist for UTP. Figures 1 and 2 indeed show a similar pattern of IP<sub>3</sub> generation after ATP and UTP. The time- and concentration-dependence for the increase in IP<sub>3</sub> levels after ATP, although measured in a different way, is similar to the results presented by Charest and co-workers (1985). Indeed they also reported a very rapid (maximal after 5s) effect of ATP on the levels of  $IP_3$  with a comparable concentration-dependence. The observation that higher concentrations of the nucleotides are needed to increase IP<sub>3</sub> levels  $(K_{\rm IP} = 50\,\mu{\rm M})$  than to activate phosphorylase  $(K_{\rm a} = 1.1\,\mu{\rm M})$  is in accordance with what is known for other cyclic AMPindependent, calcium-mediated agonists, for example vasopressin, for which the  $K_{IP}$  is about 50 fold higher than the  $K_{a}$ (Lynch et al., 1985). A very small increase in IP<sub>3</sub> seems to be sufficient to initiate the release of calcium ions into the cytosol leading eventually to the activation of phosphorylase. Since overall effects of UTP and ATP on IP<sub>3</sub> levels are identical a very similar interaction of ATP and UTP with phospholipase C is suggested. In addition to these similarities, both nucleotides also inactivate glycogen synthase and lower the levels of cyclic AMP in an identical way (Figure 2). Furthermore they are, in combination with glucagon, equally potent in synergistically activating glycogen phosphorylase (Figure 3). Four other experiments further illustrate the similarity between ATP and UTP. First, phorbol myristic acid, previously shown to increase the  $K_a$  for the activation of phosphorylase by ATP (Keppens & De Wulf, 1991) equally increases the  $K_a$  for the activation of phosphorylase by UTP. Second,  $\alpha,\beta$ -methylene-ATP, described as a  $P_{2x}$ -desensitizing agent (Burnstock & Kennedy, 1985) has no effect on the glycogenolytic potency of either UTP or ATP. Third, the use of a  $P_2$ -antagonist



**Figure 4** The effect of suramin and procion-blue on the glycogenolytic potency of ATP, UTP and vasopressin Hepatocytes were pre-incubated for 20 min at 37°C with 10 mM glucose. They were then further incubated as such (control,  $\bigcirc$ ) or challenged with suramin (20  $\mu$ M  $\blacksquare$ , 400  $\mu$ M  $\square$ ) or procion blue (20  $\mu$ M ▲, 400  $\mu$ M △). One min later the cells were treated with the indicated concentrations of ATP (a), UTP (b) or vasopressin (c). The activity of glycogen phosphorylase was determined 20s after the addition of ATP and of UTP, or 1 min after vasopressin. Data shown are from one representative experiment.



Figure 5 The non-additivity of the effects of ATP and UTP on the levels of inositol trisphosphate (IP<sub>3</sub>). Hepatocytes were pre-incubated for 20 min at 37°C with 10 mM glucose. They were then challenged with supramaximal concentrations of ATP (1 mM), UTP (1 mM) or vasopressin (1  $\mu$ M), either alone or in combination with each other. IP<sub>3</sub> levels were estimated 5s later. Data shown are the means of two independent experiments, done in duplicate. Control value for IP<sub>3</sub> was 18.1 pmol mg<sup>-1</sup> of protein.

(suramin) and a  $P_{2Y}$ -antagonist (procion blue) did not succeed in discriminating between the effects of ATP and UTP on glycogenolysis. Finally, there was no additivity of the effect of ATP and UTP on the levels of IP<sub>3</sub>, in clear contrast to the

#### References

- BERRIDGE, M.J. & IRVINE, R.F. (1989). Inositol phosphates and cell signalling. *Nature*, 341, 197–205.
- BREDT, D.S., MOUREY, R.J. & SNYDER, S.H. (1989). A simple, sensitive, and specific radioreceptor assay for inositol 1,4,5-trisphosphate in biological tissues. *Biochem. Biophys. Res. Commun.*, 159, 976–982.

additivity of vasopressin with either ATP or UTP (Figure 5). The overall conclusion to be drawn from these data is that no difference exists between the effects of ATP and UTP. In the light of the recently proposed receptor sub-classification by O'Conner *et al.* (1991) the liver would belong to those tissues with a heterogeneous 'mixed' receptor population, characterized by the rank order of glycogenolytic potency: 2-methylthio-ATP > ATP = UTP = ADP.

Our data showing a complete similarity between the effects of ATP and UTP on the liver parenchymal cell do not necessarily contradict the results reported by the group of Häussinger (1987, 1988) using the liver perfusion technique. They speculated that the differences observed between ATP and UTP might be due to their respective capacities to induce the release of thromboxane from non-parenchymal cells (Häussinger et al., 1988). Thromboxane on its own induces glycogenolysis in hepatocytes, thereby obscuring a direct effect of the nucleotides on the parenchymal cell. Our results clearly show that with a suspension of parenchymal cells, no difference between ATP and UTP is detected, suggesting a close similarity (or identity) between the ATP and UTP receptors. These data are in accord with those of Pfeilschifter (1990) on the effects of extracellular ATP and UTP on rat renal mesangial cells and those of Davidson and co-workers (1990) on pituitary cells. The authors concluded that there are probably no separate purino- and pyrimidino-ceptors on these cells. A similar situation might therefore exist for the liver parenchymal cells with ATP and UTP using a common receptor.

This work was supported by the Belgian N.F.W.O. We thank G. Cumps for skilful technical assistance, M. Coppens for secretarial help and G. Droogmans for help with the illustrations.

- BURNSTOCK, G. & KENNEDY, C. (1985). Is there a basis for distinguishing two types of P<sub>2</sub>-purinoceptor? Gen. Pharmacol., 16, 433-440.
- BURNSTOCK. G. & WARLAND, J.J.I. (1987). P<sub>2</sub>-purinoceptors of two subtypes in the rabbit mesenteric artery: Reactive blue 2 selec-

tively inhibits responses mediated via the  $P_{2Y}$ - but not the  $P_{2X}$ -purinoceptor. Br. J. Pharmacol., 90, 383-391.

- CHAREST, R., BLACKMORE, P.F. & EXTON, J.H. (1985). Characterization of responses of isolated hepatocytes to ATP and ADP. J. Biol. Chem., 260, 15789-15794.
- DAVIDSON, J.S., WAKEFIELD, I.K., SOHNIUS, U., VAN DER MERWE, P.A. & MILLAR, R.P. (1990). A novel extracellular nucleotide receptor coupled to phospholipase-C in pituitary cells. *Endocrinol.*, 126, 80-87.
- DUNN, P.M. & BLAKELEY, A.G.H. (1988). Suramin: a reversible P<sub>2</sub>-purinoceptor antagonist in the mouse vas deferens. Br. J. Pharmacol., 93, 243-245.
- GILMAN, A.G. (1970). A protein binding assay for adenosine 3': 5'cyclic monophosphate. Proc. Natl. Acad. Sci. U.S.A., 67, 305-312.
- GORDON, J.L. (1986). Extracellular ATP: effects, sources and fate. Biochem. J., 233, 309-319.
- HÄUSSINGER, D., BUSSHARDT, E., STEHLE, T., STOLL, B., WETT-STEIN, M. & GEROK, W. (1988). Stimulation of thromboxane release by extracellular UTP and ATP from perfused rat liver. Eur. J. Biochem., 178, 249-256.
- HÄUSSINGER, D., STEHLE, T. & GEROK, W. (1987). Actions of extracellular ATP and UTP in perfused rat liver. Eur. J. Biochem., 167, 65-71.
- KEPPENS, S. & DE WULF, H. (1985). P<sub>2</sub>-purinergic control of liver glycogenolysis. Biochem. J., 231, 797-799.
- KEPPENS, S. & DE WULF, H. (1986). Characterization of the liver P<sub>2</sub>-purinoceptor involved in the activation of glycogen phosphorylase. Biochem. J., 240, 367–371.
- KEPPENS, S. & DE WULF, H. (1991). Characterization of the biological

effects of 2-methylthio-ATP on rat hepatocytes: clear-cut differences with ATP. Br. J. Pharmacol., 104, 301-304.

- LEATHERBARROW, R.J. (1987). Enzfitter, a Non-Linear Regression Data Analysisprogram for the IBM PC. Amsterdam, The Netherlands: Elsevier Science Publishers BV.
- LYNCH, C.J., BLACKMORE, P.F., CHAREST, R. & EXTON, J.H. (1985). The relationships between receptor binding capacity for norepinephrine, angiotensin II, and vasopressin and release of inositol trisphosphate, Ca<sup>++</sup> mobilization and phosphorylase activation in rat liver. *Mol. Pharmacol.*, 28, 93–99.
- MVUMBI, L., BOLLEN, M. & STALMANS, W. (1985). Calcium and glycogen act synergistically as inhibitors of hepatic glycogen-synthase phosphatase. *Biochem. J.*, 232, 697-704.
- O'CONNER, S.E., DAINTY, I.A. & LEFF, P. (1991). Further subclassification of ATP receptors based on agonist studies. *Trends Pharmacol. Sci.*, 12, 137–141.
- PFEILSCHIFTER, J. (1990). Comparison of extracellular ATP and UTP signalling in rat renal mesangial cells. *Biochem. J.*, 272, 469–472.
- SEIFERT, R. & SCHULTZ, G. (1989). Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracyl nucleotides. *Trends Pharmacol. Sci.*, 10, 365-369.
- VANDENHEEDE, J.R., KEPPENS, S. & DE WULF, H. (1976). The activation of liver phosphorylase b kinase by glucagon. FEBS Lett., 61, 213-217.
- WORLEY, P.F., BARABAN, J.M., SUPATTAPONE, S., WILSON, V.S. & SNYDER, S.H. (1987). Characterization of inositol trisphosphate receptor binding in brain. J. Biol. Chem., 262, 12132–12136.

(Received September 11, 1991 Revised October 2, 1991 Accepted October 14, 1991)